|  |
| --- |
| **Supplementary Table 4S. Anti-EBOV NP IgG Responses on Study Day from Experiment 2** |
| Group | AnimalID | Anti-EBOV NP IgG ELISA (EU/mL) by study day |
| -7 | 6/7 | 14 | 28 | 70 |
| EI: Irrelevant Tc hIgG control | 1 | NT | NT | NT | NT | NT |
| 2 | NT | NT | NT | NT | NT |
| EI: SAB-139/V6-V8 | 3 | <LOQ | 90 | 2,253 | 552 | <LOQ |
| 4 | <LOQ | 128 | 340 | 2,408 | <LOQ |
| 5 | 200 | 353 | 8,007 | 2,255 | 149 |
| 6 | 187 | 256 | 384 | 456 | <LOQ |
| 7 | <LOQ | <LOQ | 557 | 237 | <LOQ |
| 8 | 387 | 464 | 1,160 | 775 | <LOQ |
| DI: SAB-139/V6-V8 | 9 | <LOQ | <LOQ | 5,621 | 2,120 | NT |
| 10 | <LOQ | <LOQ | 12,454 | 3,149 | <LOQ |
| 11 | 87 | 121 | 1,116 | 1,810 | NT |
| 12 | <LOQ | <LOQ | 27,727 | 7,545 | 308 |
| 13 | <LOQ | <LOQ | 2,879 | 2,489 | <LOQ |
| 14 | <LOQ | <LOQ | 806 | 307 | <LOQ |

Humoral responses to EBOV NP (a protein not recognized by the SAB-139) confirm infection of the NHPs with EBOV Makona isolate. Abbreviations: DI, delayed intervention (treatment initiated day 3 postexposure); EBOV, Ebola virus; EI: early intervention (treatment initiated d 1 postexposure); EU, ELISA units; ID, identification number; LOQ, limit of quantification; NP, nucleoprotein; NT, not tested; Tc hIgG transchromosomic human immunoglobulin G.